<SEC-DOCUMENT>0001193125-15-368279.txt : 20151109
<SEC-HEADER>0001193125-15-368279.hdr.sgml : 20151109
<ACCEPTANCE-DATETIME>20151105161000
ACCESSION NUMBER:		0001193125-15-368279
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20151105
FILED AS OF DATE:		20151105
DATE AS OF CHANGE:		20151105

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Prima BioMed Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		151200708

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		612 9276 1224

	MAIL ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d69831d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">6-K</FONT> </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF
FOREIGN PRIVATE ISSUER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE <FONT STYLE="white-space:nowrap">13A-16</FONT> OR
<FONT STYLE="white-space:nowrap">15D-16</FONT> UNDER THE </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Dated November 5, 2015 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number <FONT STYLE="white-space:nowrap">001-35428</FONT> </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>P<SMALL>RIMA</SMALL> B<SMALL>IO</SMALL>M<SMALL>ED</SMALL> L<SMALL>TD</SMALL> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name as Specified in its Charter) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of Registrant&#146;s Name) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level 7, 151 Macquarie Street </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Sydney, 2000 New South Wales, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by
check mark whether the registrant files or will file annual reports under cover of Form <FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT STYLE="white-space:nowrap">40-F.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form
<FONT STYLE="white-space:nowrap">20-F&nbsp;&nbsp;</FONT><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form <FONT STYLE="white-space:nowrap">40-F&nbsp;&nbsp;</FONT><FONT
STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT
STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b) (1):&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by
Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b) (7):&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;
&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicate below the file number assigned to the
registrant in connection with Rule 12g3-2(b): Not applicable. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: November 5, 2015 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="80%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><B>Prima BioMed Ltd</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc Voigt</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Marc Voigt</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:25.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:75.45pt; font-size:8pt; font-family:Times New Roman"><B>Description of Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Prima BioMed will Present at the ICI Europe Meeting in Germany, November 16-18, 2015</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d69831dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g69831g60s68.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5&nbsp;November 2015 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">PRIMA BIOMED WILL PRESENT
AT THE ICI EUROPE MEETING IN GERMANY, </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">NOVEMBER 16-18, 2015 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SYDNEY, AUSTRALIA&#151;Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) (&#147;Prima&#148; or the &#147;Company&#148;) today announced that
Dr.&nbsp;Fr&eacute;d&eacute;ric Triebel, Chief Scientific and Medical Officer, will be presenting at the forthcoming Immune Checkpoint Inhibitors Europe meeting (ICI Europe), to be held at Bad Homburg in Germany from 16 to 18 November. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ICI Europe, focused exclusively on checkpoint modulators, will see experts from a variety of established and emerging pharma companies discussing matters such
as clinically relevant biomarkers and preclinical models in immune-oncology, as well as combination strategies for clinical development. Dr.&nbsp;Triebel&#146;s presentation will take place during a segment looking at the discovery of novel immune
checkpoint pathways and will discuss LAG-3 as a &#145;next generation&#146; checkpoint. In his presentation Dr.&nbsp;Triebel will show some of the pre-clinical data generated for Prima&#146;s lead compound, IMP321, a first-in-class Antigen
Presenting Cell-Activator, as well as the Phase IIa data in metastatic breast cancer in conjunction with paclitaxel. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Event: Immune Checkpoint Inhibitors
Europe </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: Wednesday 18&nbsp;November 2015 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Time: 2:15
p.m. (Central European Time) </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Location: Maritim Hotel, Bad Homburg, Hesse, Germany </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Prima BioMed </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prima BioMed is a globally active
biotechnology company that is striving to become a leader in the development of immunotherapeutic products for the treatment of various types of cancer. Prima BioMed is dedicated to leveraging its technology and expertise to bring innovative
treatment options to market for patients and to maximise value to shareholders.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prima&#146;s current lead product is IMP321, based on the LAG-3 immune
control mechanism which plays a vital role in the regulation of the T cell immune response. IMP321, which is a soluble LAG-3Ig fusion protein, is a first-in-class Antigen Presenting Cell (APC) activator which has completed early Phase II trials. As
an APC activator IMP321 boosts the network of dendritic cells in the body that can respond to tumour antigens for a better anti-tumour CD8 T cell response. A number of additional LAG-3 products including antibodies for immune response modulation in
autoimmunity and cancer are being developed by large pharmaceutical partners.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Prima BioMed Ltd</B>, Level 12, 95 Pitt Street, Sydney NSW
2000 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Phone: +61 2 8315 7003 Fax: +61 2 8569 1880 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">www.primabiomed.com.au ABN: 90 009 237 889 </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prima BioMed is listed on the Australian Stock Exchange, and on the NASDAQ in the US. For further information
please visit <U>www.primabiomed.com.au</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The presentation slides for this event will be made available for downloading from Prima&#146;s website
closer to the date of the event. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>For further information please contact: </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Prima BioMed Ltd: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stuart Roberts </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 (0)&nbsp;447 247 909; <U>stuart.roberts@primabiomed.com.au</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australia Investor/Media: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr Matthew Gregorowski,
Citadel-MAGNUS </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 (0)&nbsp;422 534 755; <U>mgregorowski@citadelmagnus.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Investors: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Matthew Beck, The Trout Group LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (646)&nbsp;378-2933; <U>mbeck@troutgroup.com</U> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Prima BioMed Ltd</B>,
Level 12, 95 Pitt Street, Sydney NSW 2000 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Phone: +61 2 8315 7003 Fax: +61 2 8569 1880 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">www.primabiomed.com.au ABN: 90 009 237 889 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g69831g60s68.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g69831g60s68.jpg
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MU-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M44LGEH2VV-CC )KL+;Q=X5O?"</CRT\1Z'=>";C0!XJ@\6V^J0R^&YM,-O\
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M_P"(OA597\3>!/#7CC3=;\7>'Q#(L4QO-.AF:>$([JC>8@PS 'DU>^*'QO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MYXLU/P/\5_A5X[NX]<TW4=-LCINH'2#<*@:6.XA:Z,<C@2Q36Z,K8+ _J/\
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M&FD_%K35TCX@V>C27#Q^);=89X%BG,DC' CN)5XQPYK[7HHNWNQ\TC\>HO\
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MP:.A.E?$GQ<@D8.Z3>(;F5#C.,;BWOQC%=!;?M-?'V$,?^%E^($?S-PS/'>
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M_P""JG^9_<M_:6F_\_\ 9_\ @7'_ (T?VEIW:^L\8Y_TI#_6OX:?^%@^/O\
MH>_&G_A5W_\ \=I&\?\ CYD96\=>-"I'S#_A*[\?^U:/^(X99TP-3_P*(+Z
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MH'=]S)O=!T/401J&BZ3?AE*L+W3H;K<#G(.Y3UR?SKRWQ-^SE\"O&,;QZ_\
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M#>,>7+EHYY4DO^GD:=3\9P;_ !/P#U?_ ()2_&H.[VOCCP3JR[CY221RV?E
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M\#/AK.P9G5I/"UJQ1F^]CY>,^U8<_P"P[^R/-&8S^S]\,X@X*DVWAJ&U;\T
MY]".F:PJ>"&=QBW2QE)OHFI)?-VE^1]/3^GYPM*25;A[$):;5J;]='&*?WH_
MC(N9)VC#0+.A63)RH *X.1[_ /UJC>:5FCV$KCY3O!)SC&>PY]#7]@>K_P#!
M.#]C#7%;[;\$]'B)) .EZUJFD%"1C*^3<ICI7ENI_P#!(W]C&^XM/"WC31N
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M^GP_TG_H^XM_N^*<.O*2K0_]*IQ/QI<Y?(VJ"<;5.1T[?E25^JFI_P#!&_\
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/IJFN(I/UH89O_P!,G__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
